key: cord-271090-91lzr4tz
authors: Edwards, Kathryn M.; Orenstein, Walter A.
title: Anticipating SARS-CoV-2 Vaccine Testing, Licensure, and Recommendations for Use
date: 2020-06-19
journal: J Pediatr
DOI: 10.1016/j.jpeds.2020.06.048
sha: 
doc_id: 271090
cord_uid: 91lzr4tz

nan

vaccines; the WHO has listed over 120 candidates in various stages of development (2) . As we quickly embark on the pursuit of vaccines to prevent COVID-19 disease, many are concerned that the rapidity with which these studies are being conducted will mean that vaccine safety will be sacrificed. However, over the past several decades existing procedures to test and license vaccines, to regulate their production and purity, and advisory bodies to guide their use have been established and refined and are well prepared to ensure safe and effective vaccines. In this brief review, we will outline these processes from our perspectives. Both of us have been working in the vaccine field for four decades; we provide reassurance that the process is well established and designed to provide safe and effective vaccines.

Similar to the development of pharmaceutical agents, vaccine development progresses through preclinical and three distinct clinical stages, Phase 1, 2, and 3 (3, 4) .

First comes the development of a vaccine candidate with the potential to stimulate a protective immune-CoV-response that will prevent disease upon encounter with the pathogen. SARS 2 is a new coronavirus and we do not have a clear understanding of what is needed for a protective immune response. For many vaccines the generation of an antibody directed to an important component of the virus is associated with protection. In the case of SARS-CoV-2, most candidate vaccines have been designed to generate an immune response to the spike protein, the attachment protein of the virus. Proposed vaccine constructs present the spike antigen as mRNA or DNA, as part of a nonreplicating or replicating viral vector such as adenovirus or vesicular stomatitis virus, as an inactivated whole virus, or as a purified protein (5, 6) .

Initially these proposed vaccines are administered in preclinical studies to small animals, often mice, and their immune responses are measured. Generation of immunity against the virus must be demonstrated or the vaccine would not undergo further testing. Toxicity studies also are conducted in animals to detect safety signals. With SARS-CoV-2, non-human primates increasingly are being used for studies in which vaccination is followed by challenge of the animals with wild type SARS-CoV-2 (7, 8 ) . Because of concerns raised about enhanced disease after wild virus infection in animal studies following vaccination against severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and Middle East respiratory syndromecoronavirus (MERS-CoV) (9, 10), experts have met and proposed immunologic criteria to be evaluated in animals and humans to detect and consequently reduce the risk of enhanced disease (11) . These criteria include generation of functional antibody capable of virus neutralization and T-lymphocyte responses with a TH1 phenotype.

When preclinical studies in animals demonstrate that the vaccine stimulates an immune response and there are no toxicity concerns, vaccines then undergo Phase 1 clinical trials.

Phase 1 study proposals must be presented to the FDA and approved prior to the start of the study. These trials enroll limited numbers of healthy subjects, usually less than 100 individuals, between the ages of 18 to approximately 55 years primarily to test the safety of the new experimental vaccine, although immunogenicity is also measured. Subjects enrolled in Phase 1 studies are well informed about the risks and the potential benefits of the vaccines and are screened for their ability to be monitored closely and to adhere to rigorous safety assessments. composed of vaccine experts, independent of the study site investigators and sponsors of the study, who assess the reactions and approve the advancing of the dose level based on the safety profile of the administered vaccines. All Phase 1 studies also have halting rules, so that if severe reactions are seen, the study will be stopped. These halting rules might include hospitalization for a vaccine-related event or a severe reaction attributed to the vaccine in several participants. All participants in the trials have immunologic studies performed as well to determine the height of the antibody responses, the function of the antibody generated, and Tlymphocyte responses to the vaccines. As mentioned above, the sample sizes of these Phase 1 studies are usually less than 100 individuals, based on the safety of the administered vaccine and the doses that are proposed to be tested. Some of the Phase 1 studies evaluating SARS-CoV-2 vaccines have also included individuals >65 years of age to assess safety and immunogenicity in this population, which is at greater risk for severe COVID-19 disease. At the conclusion of the Phase 1 trial, the safety and immunogenicity data are reviewed and presented to the FDA for approval to advance to Phase 2 studies.

Phase 2 studies involve several hundred subjects and often have a larger age range than Phase 1 trials. With SARS-CoV-2 vaccines, Phase 2 studies are planned to expand the safety profile and to assess immune responses in larger numbers of subjects. Again, meticulous attention to safety assessment is included in these studies, also with the input of independent DSMCs to assess the reaction profile. Finally, if Phase 2 studies confirm safety and immunogenicity in the expanded populations and with approval of the FDA, Phase 3 trials can begin.

Phase 3 trials are designed to determine whether the vaccines will prevent a predefined endpoint, generally the prevention of laboratory confirmed disease. Subjects enrolled in Phase 3 studies are randomized and blinded to receipt of either vaccine or a control, usually consisting of a placebo. Subjects and investigators also are blinded to group assignment and remain so throughout the Phase 3 trial. After injection, study participants are followed closely and if they should develop predefined symptoms of disease they are tested for the presence of the virus.

The determination of the primary endpoint of the study and the accepted level of vaccine efficacy of the vaccine for the study can be a complicated endeavor. The WHO and other international groups are advocating for standard definitions for the efficacy trials and standard immunologic assays assessing the SARS-CoV-2 vaccine responses so that the multiple tested vaccines ultimately can be compared with each other. The Phase 3 efficacy trials planned for SARS-CoV-2 vaccines in the United States are expected to enroll 20,000 to 30,000 individuals, the numbers projected to be necessary to determine whether the vaccines will prevent significant disease over a period of 6 months follow-up. Obviously, this will depend on the attack rate in the control group, with higher rates of infection associated with less time needed to determine vaccine efficacy. Each trial will be targeted for a defined number of cases detected and when that number of cases has been reported, the efficacy will be assessed. Ideally, one of the results of the phase 3 trial will be determination of a serologic correlate of protection. For example, a correlate could be an antibody level associated with protection from disease. This would facilitate evaluation of the vaccine in population groups not involved in the original trial, such as children, since it would not require assessment of actual protection from disease. While this is a highly sought-after endpoint, it is not always possible to validate such a correlate of protection (12) .

At the conclusion of the Phase 3 efficacy trial the study data will be presented to the FDA who ultimately will decide whether the vaccine will be licensed. The level of efficacy that will be accepted for licensure of a SARS-CoV-2 vaccine remains a complicated question. In the face of the outbreak, would a vaccine that is 50% efficacious be acceptable for licensing? Those decisions will be part of the licensure process. The FDA will also require the vaccine producer to label the product for how it will be used, based on the data generated in the Phase 3 clinical trial. The FDA will seek the guidance of a standing advisory group of experienced clinicians, vaccine experts, epidemiologists, and other subject matter experts, called the Vaccine and Related Biologic Products Advisory Committee (VRBPAC), to advise the FDA whether the vaccine should be licensed. VRBPAC often has one or two pediatricians as members. The FDA poses specifically focused questions to the VRBPAC that relate to both vaccine efficacy and vaccine safety. All the adverse events reported in clinical trials will be comprehensively presented and discussed with the committee. Any significant safety concern raised may delay licensure or additional safety studies may be proposed. Ultimately the FDA will seek the guidance of the VRBPAC, but will decide as an agency whether the vaccine will be licensed and what limitations will be placed on the licensure. 

Given the constrained timeline for testing and the need for rapid deployment of the SARS-CoV-2 vaccines, manufacturing capabilities will need to be established before the conclusion of the efficacy trials. This will entail financial outlays for building production facilities for new vaccines before they have been shown to be effective. For example, since there are no existing licensed vaccines using the mRNA or DNA technology, these manufacturing facilities would need to be established should these constructs move toward licensure. Globally, most vaccines are manufactured by five companies based in the US and Europe (13, 14) , geographically at a distance from underserved areas where SARS-CoV-vaccines are needed. Financial support from governments, nongovernmental organizations, and philanthropic organizations will be needed during this time to produce the required number of vaccines to fully immunize the 7 billion inhabitants of the world. To facilitate rapid availability of COVID-19 vaccines, the US Government has agreed to finance production of millions of doses of vaccine prior to completion of the phase 3 trials for promising candidates (15) . This reduces manufacturer risk, should the vaccine be found ultimately not to merit licensure.

In addition, most vaccines are administered by a healthcare worker via needle and syringe and this approach undoubtedly will be used for many COVID-19 vaccines. It will be challenging to rapidly mobilize a large experienced vaccinator workforce during a pandemic. Novel administration technologies might also include microneedle array patches, reconstitution administration devices, and jet injectors. Not requiring a needle and syringe could make it easier for non-technical persons to be trained to administer vaccine and to facilitate uptake, but innovative approaches to delivery also will need to be evaluated for safety and immunogenicity before they can be widely employed.

Vaccines do not save lives. Vaccinations save lives. A vaccine dose that remains in the vial is 0% effective. Once a SARS-CoV-2 vaccine is licensed for use in the US, recommendations will need to be made as to who should receive it and who should not, any groups who should be at higher priority for vaccination compared with other groups, the optimal immunization schedule including addressing the need for boosters, catch-up vaccination for those older than those who would be recommended for ongoing routine vaccination, and more. Systems need to be in place to provide access to vaccines and to remove barriers to access, such as cost. Ongoing monitoring of vaccine effectiveness and safety are critical to evaluate issues such as: waning immunity, groups at heightened risk for vaccine failure, and to determine adverse events following vaccination that are causally related, especially rare events that could not be detected in pre-licensure trials. Estimations of the burden of causally vaccine-related adverse events can then be weighed against the benefits of the vaccine to determine if any changes in recommendations are warranted. Disease surveillance is crucial to determine who continues to acquire disease, risk factors for disease, and the role of vaccine failure versus failure to vaccinate in disease prevention. is an entitlement program for all ACIP approved vaccines for eligible children (19, 20) . Eligible children include those on Medicaid, those who are completely uninsured, and American Indian/Alaskan Natives. Approximately 50% of children are covered by VFC (21) . In addition, Federal grants to states can be used to purchase vaccines to cover other children (22) . The Affordable Care Act requires private insurers to cover ACIP recommended vaccines at innetwork providers.

Clinical trials usually are conducted with thousands of participants and in some trials, tens of thousands, as planned with SARS-CoV-2 vaccines. However, once approved for use, vaccines Adequately assessing vaccine safety is critical to the success of immunization programs and requires an existing comprehensive system to monitor safety. In the United States, there are several systems in place to assess safety in the post-licensure setting (23). These include Vaccine Adverse Event Reporting System (VAERS), a system which allows providers, parents, and patients to report adverse events. The VAERS system functions more to raise hypotheses about whether receipt of a vaccine or vaccines causes the adverse event rather than to evaluate causation. The Vaccine Safety Datalink (VSD) is a collaborative project between CDC's Immunization Safety Office and eight health care organizations. The VSD was initiated in 1990 and continues today in order to monitor safety of vaccines over large populations and to conduct studies to assess rare and serious adverse events following immunization. The Center for Immunization Safety Assessment (CISA) is a national network of vaccine safety experts from the CDC's Immunization Safety Office (ISO), seven medical research centers, and other partners, which provides a comprehensive vaccine safety public health service to the nation.

Most vaccine-preventable diseases are transmitted person-to person. Thus, when some individuals are vaccinated with most vaccines they are not only themselves getting an active immune response from the vaccine but also indirectly are protecting others in society who either cannot be vaccinated (e.g., have medical contraindications to vaccine) or fail to make an adequate immune response (24) . Therefore, if someone is injured by vaccine, society owes that person compensation. This is the basis for the National Vaccine Injury Compensation Program (25) . This program offers compensation for the injured vaccine recipient and reduces the risk of liability for the vaccine provider and the manufacturer since persons who receive vaccines covered by the NVICP must first go through this compensation process, and suing the provider or manufacturer is difficult. The NVICP has markedly reduced liability. During the last pandemic in 2009 of H1N1 influenza, post-licensure vaccine safety systems were established to efficiently monitor vaccine safety. It is anticipated that similar systems will also be implemented as the new SARS-CoV-2 vaccines are introduced (26, 27).

Few programs have had impact close to that of vaccines in reducing health burdens. This is the result of a rigorous system to assure that vaccines recommended are safe and effective, and of an equally rigorous system to assure that persons for whom vaccines are recommended actually receive them, especially children.

A Novel Coronavirus from Patients with Pneumonia in China

Draft landscape of COVID-19 candidate vaccines

Committee on Infectious Diseases, The Committee on Practice and Ambulatory Medicine. Countering Vaccine Hesitancy

Vaccines: Status Report. Immunity

The Challenges of Vaccine Development against a New Virus during a Pandemic

Rapid development of an inactivated vaccine candidate for SARS-CoV-2

Online ahead of print

Balancing Expediency and Scientific Rigor in SARS-CoV-2 Vaccine Development

Rapid COVID-19 vaccine development

Consensus considerations on the assessment of the risk of disease enhancement with COVID-19 vaccines

Apr Available from

Correlates of protection induced by vaccination. Clin Vaccine Immunol

The complexity and cost of vaccine manufacturing -An overview

Vaccine Manufacturing. Plotkin's Vaccines 7 th edition

White House Narrows Candidates for Vaccine to Five Companies

The history of the United States Advisory Committee on Immunization Practices (ACIP)

Immunization in the United States in Plotkin's Vaccines 7 th edition

Benefits from immunization during the Vaccines for Children program era-United States

Protecting the Public's Health: Critical Functions of the Section 317 Immunization Program-A Report of the National Vaccine Advisory Committee

Community Protection in Plotkin's Vaccines 7 th edition

Legal Issues in Plotkin's Vaccines 7

Monitoring vaccine safety using the Vaccine Safety Datalink: utilizing immunization registries for pandemic influenza

H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System